ENSC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ensysce Biosciences Inc (ENSC) is not a strong buy for a beginner long-term investor at this time. The company's financial performance is significantly weak, with substantial revenue and net income declines. While the stock has shown some short-term technical positivity, there are no strong trading signals or catalysts to suggest a compelling long-term growth opportunity. The lack of insider or hedge fund activity, coupled with no recent congress trading data, further supports a cautious approach.
The MACD is positive but contracting, suggesting weakening bullish momentum. RSI is neutral at 58.743, and moving averages are converging, indicating no clear trend. Key support and resistance levels show limited upside potential in the short term, with a pivot at 0.531 and resistance at 0.691.
The company has initiated a formal review of strategic alternatives to enhance shareholder value, which could lead to potential partnerships or capital strategies.
EPS has also dropped sharply. There is no significant insider or hedge fund activity, and no recent congress trading data.
In Q3 2025, revenue dropped to $493,104 (-85.58% YoY), net income dropped to -$3,729,128 (-663.51% YoY), and EPS fell to -1.29 (-229.00% YoY). Gross margin remained stable at 100%.
No recent analyst ratings or price target changes are available for ENSC.
